Patents Assigned to BioCryst, Inc.
  • 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
    Patent number: 5189039
    Abstract: Disclosed is a compound of the formula ##STR1## wherein R.sup.1 is H, NH.sub.2, or OCH.sub.3, R.sup.2 is an optionally substituted cyclic group optionally containing one or more heteroatoms, R.sup.3 and R.sup.4 are independently H or C.sub.1-4 alkyl, m is 0-4, n is 0-6, p is 0.1, X is CN, CSNH.sub.2, PO(OH).sub.2, COOH, SO.sub.2 NH.sub.2, NH.sub.2, OH, CNHNH.sub.2, tetrazole, triazole, or COR.sup.5 where R.sup.5 is C.sub.1-4 alkyl, CF.sub.3, NH.sub.2, or OC.sub.1-4 alkyl, and Y is O or NH that is useful as a pharmaceutical.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: February 23, 1993
    Assignee: BioCryst, Inc.
    Inventors: Shri Niwas, John A. Secrist, III, John A. Montgomery, Mark D. Erion, Wayne C. Guida, Steve E. Ealick
  • 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
    Patent number: 5008265
    Abstract: Disclosed is a compound containing a 2-amino-7-(substituted methyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one wherein substituted methyl is --CH.sub.2 --R wherein R is an optionally substituted alicyclic group, a pharmaceutical composition containing the compound, and a method for the selective suppression of mammalian T-cell function without diminished effect on humoral immunity which involves administering the composition to a mammal.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: April 16, 1991
    Assignee: BioCryst, Inc.
    Inventors: John A. Secrist, III, John A. Montgomery, Steve E. Ealick, Mark D. Erion, Wayne C. Guida
  • 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
    Patent number: 5008270
    Abstract: Disclosed is a compound containing a 2-amino-7-(substituted methyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one wherein substituted methyl is --CH.sub.2 --R wherein R is an optionally substituted heteroalicyclic group, a pharmaceutical composition containing the compound, and a method for the selective suppression of mammalian T-cell function without diminished effect on humoral immunity which involves administering the composition to a mammal.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: April 16, 1991
    Assignee: BioCryst, Inc.
    Inventors: John A. Secrist, III, John A. Montgomery, Steve E. Ealick, Mark D. Erion, Wayne C. Guida
  • 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
    Patent number: 4985434
    Abstract: Disclosed is a compound containing 2-amino-7-(R)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one wherein R is optionally substituted cyclohexenyl or cyclohexyl, a pharmaceutical composition containing the compound, and a method for the selective suppresion of mammalian T-cell function without diminished effect on humoral immunity which involves administering the composition to a mammal.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: January 15, 1991
    Assignee: Biocryst, Inc.
    Inventors: John A. Secrist, III, John A. Montgomery, Steve E. Ealick, Mark D. Erion, Wayne C. Guida
  • 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
    Patent number: 4985433
    Abstract: Disclosed is a compound containing a 2-amino-7-(substituted methyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one wherein substituted methyl is --CH.sub.2 --R wherein R is optionally substituted pyridinyl, a pharmaceutical composition containing the compound, and a method for the selective suppression of mammalian T-cell function without diminished effect on humoral immunity which involves administering the composition to a mammal.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: January 15, 1991
    Assignee: BioCryst, Inc.
    Inventors: John A. Secrist, III, John A. Montgomery, Steve E. Ealick, Mark D. Erion, Wayne C. Guida